LILRB2 and early-onset autosomal dominant Alzheimer disease: In Alzheimer’s disease, soluble β-amyloid (Aβ) oligomers were known to lead to synaptic loss associated with AD, And human LILRB2 was a β-amyloid receptor, so blocking the function of LILRB2 is a potential therapeutic target for AD, (Kim et al., 2013).